J&J, Novartis Fined $22.4M Over Pay-For-Delay Deal

Law360, New York (December 10, 2013, 1:06 PM EST) -- Drugmakers Johnson & Johnson and Novartis AG on Tuesday were hit with a total of €16.3 million ($22.4 million) in fines by European regulators for entering into an anti-competitive agreement to delay the introduction of a generic painkiller in the Netherlands.

The European Commission said in 2005 that the respective Dutch subsidiaries of Novartis and J&J entered into a deal to prevent the entry of a generic version of J&J's fentanyl, after the protection on its brand-name fentanyl depot patch expired in the Netherlands, just as Novartis unit Sandoz BV was poised to launch its own fentanyl patch.

"J&J paid Novartis...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS